Neurodegenerative Disease Program

About Scripta Therapeutics

Scripta Therapeutics is an AI-driven biotech pioneering a novel approach to drug discovery by targeting transcription factors. The company has built a proprietary platform that integrates genome-wide mapping of transcription factors, AI/ML-driven prediction of modulators, and validation in patient-derived models to identify transformative therapeutics. Backed by a consortium of venture capital firms and led by a team with deep pharma, biotech, and computational expertise, Scripta is initially applying its platform to high-unmet-need neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS with the ambition to halt or reverse disease progression.

About Origami Therapeutics

Origami Therapeutics is an early-stage biotech pioneering a novel approach to treating disease by developing small molecules that target and degrade disease-causing proteins. The company is leveraging protein degradation technology, aiming for selectivity and broad tissue distribution, with an initial focus on major neurodegenerative conditions like Alzheimer's, Parkinson's, and Huntington's diseases. As a private, preclinical-stage company, it is positioned in the competitive but high-potential field of targeted protein degradation, seeking to address significant unmet medical needs.

Therapeutic Areas

Other Alzheimer's, Parkinson's, ALS Drugs